[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silence Therapeutics Plc (SLN.LN)

Silence Therapeutics Plc (SLN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silence Therapeutics Plc 12 Hammersmith Grove London W6 7AP GBR

https://www.silence-therapeutics.com P: 203-457-6900

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Key Statistics

Overview:

Market Capitalization, $K 480,348
Shares Outstanding, K 89,785
% of Insider Shareholders 70.46%
% of Institutional Shareholders 2.37%

Financials:

Annual Sales, $ 559 K
Annual Net Income, $ -88,612 K
Last Quarter Sales, $ 422 K
Last Quarter Net Income, $ -14,957 K

Growth:

1-Year Return 27.99%
3-Year Return 522.09%
5-Year Return 390.83%
5-Year Revenue Growth -40.45%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.49
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 04/30/13

SLN.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -49.96%
Profit Margin % -15,851.88%
Debt/Equity 0.00
Price/Sales 41.14
Price/Book 29.36
Book Value/Share 0.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.